1. Home
  2. PRLB vs SGP Comparison

PRLB vs SGP Comparison

Compare PRLB & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Proto Labs Inc.

PRLB

Proto Labs Inc.

BUY

Current Price

$57.34

Market Cap

1.1B

Sector

Industrials

ML Signal

BUY

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$26.85

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRLB
SGP
Founded
1999
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
932.9M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
PRLB
SGP
Price
$57.34
$26.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$53.00
$47.00
AVG Volume (30 Days)
203.4K
82.4K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
33.33
N/A
EPS
0.88
N/A
Revenue
N/A
N/A
Revenue This Year
$8.56
N/A
Revenue Next Year
$6.89
N/A
P/E Ratio
$69.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.20
$24.71
52 Week High
$68.91
$30.56

Technical Indicators

Market Signals
Indicator
PRLB
SGP
Relative Strength Index (RSI) 39.22 53.08
Support Level $47.24 $25.50
Resistance Level $68.91 $30.02
Average True Range (ATR) 2.21 1.60
MACD -1.00 -0.30
Stochastic Oscillator 0.68 29.00

Price Performance

Historical Comparison
PRLB
SGP

About PRLB Proto Labs Inc.

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: